首页> 外文期刊>Applied cancer research. >Use of uracil-DNA glycosylase enzyme to reduce DNA-related artifacts from formalin-fixed and paraffin-embedded tissues in diagnostic routine
【24h】

Use of uracil-DNA glycosylase enzyme to reduce DNA-related artifacts from formalin-fixed and paraffin-embedded tissues in diagnostic routine

机译:使用尿嘧啶-DNA糖基酶酶以减少诊断程序中的福尔马林固定和石蜡包埋组织的DNA相关伪影

获取原文
       

摘要

Detection of somatic mutations is a mandatory practice for therapeutic definition in precision oncology. However, somatic mutation detection protocols use DNA from formalin-fixed and paraffin-embedded (FFPE) tumor tissues, which can result in detection of nonreproducible sequence artifacts, especially C:G??T:A transitions, in DNA. In recent studies, DNA pretreatment with uracil DNA glycosylase (UDG), an enzyme involved in base excision repair, significantly reduced the number of DNA artifacts after mutation detection by next-generation sequencing (NGS) and other methods, without affecting the capacity to detect real mutations. This study aimed to evaluate the effects of UDG enzymatic pretreatment in reducing the number of DNA sequencing artifacts from FFPE tumor samples, to improve the accuracy of genetic testing in the molecular diagnostic routine. We selected 12 FFPE tumor samples (10 melanoma, 1 lung, and 1 colorectal tumor sample) with different storage times. We compared sequencing results of a 16-hotspot gene panel of NGS libraries prepared with UDG-treated and untreated samples. All UDG-treated samples showed large reductions in the total number of transitions (medium reduction of 80%) and the transition/transversion ratio (medium reduction of 75%). In addition, most sequence artifacts presented a low variant allele frequency (VAF??10%) which are eliminated with UDG treatment. Including UDG enzymatic treatment before multiplex amplification in the NGS workflow significantly decreased the number of artifactual variants detected in FFPE samples. Thus, including this additional step in the current methodology should improve the rate of true mutation detection in the molecular diagnostic routine.
机译:体细胞突变的检测是精密肿瘤学治疗定义的强制性实践。然而,体细胞突变检测方案使用来自福尔马林固定的和石蜡包埋(FFPE)肿瘤组织的DNA,这可能导致检测不可递冻的序列伪像,尤其是C:g?>ΔT:在DNA中的过渡。在最近的研究中,DNA预处理尿嘧啶DNA糖基酶(UDG),涉及基础切除修复的酶,通过下一代测序(NGS)和其他方法显着降低了突变检测后的DNA伪影数,而不会影响检测能力真正的突变。本研究旨在评估UDG酶预处理在减少FFPE肿瘤样品中的DNA测序浪费数量中的影响,提高分子诊断程序中遗传检测的准确性。我们选择了12个FFPE肿瘤样本(10个黑色素瘤,1肺和1个结直肠肿瘤样品),不同的储存时间。我们比较了用UDG处理和未处理的样品制备的NGS文库的16层热点基因组的测序结果。所有UDG处理的样品在过渡的总次数(中等减少80%)和过渡/转化率(中等减少75%)中表现出大的减少。此外,大多数序列伪像呈现出低变异等位基因频率(VAF?<?10%),其被UDG处理消除。在NGS工作流中的多重扩增之前,包括UDG酶处理,显着降低了在FFPE样品中检测到的艺术变体的数量。因此,包括当前方法中的该附加步骤应提高分子诊断程序中真正突变检测的速率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号